project id: TCGA-PRAD; case submitter id: TCGA-EJ-A65F; analyte type: DNA; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.83; concentration: 0.15; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.43; rna integrity number: 8.1; age at index: 59; days to birth: -21681; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1953; age at diagnosis: 21681; ajcc clinical m: M0; ajcc clinical t: T3b; ajcc pathologic n: N0; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 560.0; icd 10 code: C61; last known disease status: not reported; morphology: 8255/3; primary diagnosis: Adenocarcinoma with mixed subtypes; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 293; initial weight: 360.0; sample id: af0c6ecc-502d-46ff-b5aa-4a34d9928a6e; sample submitter id: TCGA-EJ-A65F-01A; portion id: 2820d609-1c9c-492e-8a8a-57d67b1fadc7; portion submitter id: TCGA-EJ-A65F-01A-21; slide id: db76e845-d66f-4c94-8ada-d158ed32550e; slide submitter id: TCGA-EJ-A65F-01A-02-TSB; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 20.0; percent stromal cells: 20.0; percent tumor cells: 60.0; percent tumor nuclei: 60.0; section location: TOP;